Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2025 | 2 | -$0.45 | -$0.34 | -$0.40 |
Q2 2025 | 1 | -$0.52 | -$0.26 | -$0.39 |
Q3 2025 | 1 | -$0.52 | -$0.26 | -$0.39 |
Q4 2025 | 1 | -$0.48 | -$0.24 | -$0.36 |
Q1 2026 | 1 | -$0.50 | -$0.25 | -$0.37 |
Q2 2026 | 1 | -$0.46 | -$0.23 | -$0.34 |
Q3 2026 | 1 | -$0.44 | -$0.22 | -$0.33 |
Q4 2026 | 1 | -$0.41 | -$0.20 | -$0.31 |
OncoCyte Corporation last posted its earnings results on Thursday, August 8th, 2024. The company reported $-0.36 earnings per share for the quarter, topping analysts' consensus estimates of $-0.56 by $0.2. The company had revenue of 115,000 for the quarter and had revenue of 1.50 M for the year. OncoCyte Corporation has generated $-4 earnings per share over the last year ($-3.75 diluted earnings per share) and currently has a price-to-earnings ratio of -0.66. OncoCyte Corporation has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, April 10th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
11/12/2024 | Q3 2024 | -$0.98 | $178,333 | $115,000 | ||
08/08/2024 | Q2 2024 | -$0.56 | -$0.36 | 0.2 | $318,550 | $104,000 |
05/15/2024 | Q1 2024 | -$0.67 | -$1.10 | -0.43 | $176,000 | |
04/15/2024 | Q4 2023 | -$1.94 | $314,000 | |||
11/09/2023 | Q3 2023 | -$1.52 | -$0.79 | 0.73 | $312,500 | $429,000 |
08/10/2023 | Q2 2023 | -$2.60 | -$20.60 | -18 | $362,500 | $463,000 |
05/12/2023 | Q1 2023 | $0.40 | $297,000 | |||
04/12/2023 | Q4 2022 | -$7.64 | $-3,550,000 | |||
11/10/2022 | Q3 2022 | -$2.60 | -$1.59 | 1.01 | $2.71 M | $1.02 M |
08/11/2022 | Q2 2022 | -$1.42 | $2.24 M | $2.07 M | ||
05/12/2022 | Q1 2022 | -$2.32 | $1.42 M | |||
05/02/2022 | Q4 2021 | -$7.88 | $3.59 M | |||
11/09/2021 | Q3 2021 | -$1.40 | -$3.02 | -1.62 | $1.57 M | $984,000 |
08/11/2021 | Q2 2021 | -$2.34 | $838,017 | $2.03 M | ||
05/17/2021 | Q1 2021 | -$1.80 | -$0.95 | 0.85 | $1.12 M | |
03/19/2021 | Q4 2020 | -$1.87 | $503,000 | |||
11/12/2020 | Q3 2020 | -$1.80 | -$2.02 | -0.22 | $47,200 | $555,000 |
07/29/2020 | Q2 2020 | -$2.20 | -$2.77 | -0.57 | $143,000 | |
05/12/2020 | Q1 2020 | -$2.20 | -$2.52 | -0.32 | $16,000 | |
04/28/2020 | Q4 2019 | -$2.92 | $0 |
OncoCyte Corporation has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, April 10th, 2025 based off last year's report dates.
In the previous quarter, OncoCyte Corporation (:OCX) reported $-0.36 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.56 by $0.2.
The conference call for OncoCyte Corporation's latest earnings report can be listened to online.
The conference call transcript for OncoCyte Corporation's latest earnings report can be read online.
OncoCyte Corporation (:OCX) has a recorded annual revenue of $1.50 M.
OncoCyte Corporation (:OCX) has a recorded net income of $1.50 M. OncoCyte Corporation has generated $-3.75 earnings per share over the last four quarters.
OncoCyte Corporation (:OCX) has a price-to-earnings ratio of -0.66 and price/earnings-to-growth ratio is 0.15.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED